DB-OTO Gene Therapy for Inherited Deafness.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Valayannopoulos Vassili, Bance Manohar, Carvalho Daniela S, Greinwald John H, Harvey Steven A, Ishiyama Akira, Landry Evie C, Löwenheim Hubert, Lustig Lawrence R, Manrique Manuel, Nash Robert, Polo Rubén, Pritchett Cedric V, Rubinstein Jay T, Shearer A Eliot, Del Castillo Ignacio, Anderson Jeffery J, Corrales C Eduardo, Quigley Tera M, Riggs William J, Weber Peter, Wilson Gary, Irvin Susan C, Hassan Hazem E, Chen Yanping, Liu Rong, Drummond Meghan C, Sabin Leah R, Musser Bret J, Yancopoulos George D, Kyratsous Christos A, Herman Gary A, Baras Aris, Whitton Jonathon P, CHORD Study Group
Аннотация
METHODS: We conducted an open-label, single-group, first-in-human registrational study to evaluate DB-OTO. Children with OTOF variants and profound deafness (defined by an average audiometric threshold of >90 decibel hearing level [dB HL], indicating an inability to hear a gas-powered lawn mower) received an intracochlear infusion of DB-OTO (7.2×1012 vector genomes per ear) in one or both ears. The primary efficacy end point was an average threshold on behavioral pure-tone audiometry (PTA) at week 24 of 70 dB HL or less, a clinical standard that generally avoids cochlear implantation and enables natural acoustic hearing. A key secondary end point was the presence of an auditory brain-stem response to a click stimulus at a threshold at or below 90 dB normalized hearing level (db nHL) at week 24. Safety assessments included adverse events, laboratory results, and vestibular testing.
RESULTS: A total of 12 children have been enrolled in the study. After a single infusion of DB-OTO, a PTA average threshold of 70 dB HL or less at week 24 (primary end point) and an auditory brain-stem response at or below 90 dB nHL (key secondary end point) were found in 9 of the 12 participants (75%; 95% confidence interval, 43 to 95; P = 1.1×10-13 for both end points). Six participants could hear soft speech without assistive devices, and 3 had average normal hearing sensitivity. A total of 67 adverse events occurred or worsened during or after treatment, none of which led to discontinued participation in the study.
CONCLUSIONS: DB-OTO gene therapy improved hearing in patients with OTOF-related deafness, enabling natural acoustic hearing and normalizing hearing sensitivity in 3 of 12 treated patients. (Funded by Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT05788536.).